1. Search Result
Search Result
Results for "

central nervous system (CNS)

" in MedChemExpress (MCE) Product Catalog:

64

Inhibitors & Agonists

4

Screening Libraries

1

Fluorescent Dye

1

Biochemical Assay Reagents

6

Peptides

1

MCE Kits

6

Natural
Products

3

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-163855

    Sodium Channel GABA Receptor Neurological Disease
    KGP-25 is an inhibitor of voltage-gated sodium channel 1.8 (Nav1.8), which can be used for analgesia by targeting Nav1.8 in the peripheral nervous system (PNS). KGP-25 can also target γ-aminobutyric acid subtype A receptor (GABAA) in the central nervous system (CNS) for general anesthesia .
    KGP-25
  • HY-N2321
    Salsolinol-1-carboxylic acid
    1 Publications Verification

    Others Neurological Disease
    Salsolinol-1-carboxylic acid is an endogenous alkaloid in the central nervous system (CNS) .
    Salsolinol-1-carboxylic acid
  • HY-14550A

    Phosphodiesterase (PDE) Others
    PDE10-IN-5 is a phosphodiesterase 10 (PDE 10) inhibitor, can be used for researching certain central nervous system (CNS) disorders .
    PDE10-IN-5
  • HY-160446

    Epigenetic Reader Domain Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Bet-in-24 (example 2) is a bromodomain and extra-terminal (BET) inhibitor. BET-IN-24 can be used in the study of virology, heart failure, inflammation, central nervous system (CNS) diseases and many cancers
    BET-IN-24
  • HY-163629

    Others Cancer
    Anticancer agent 224 (Compound 16) is an anticancer agent that can effectively inhibit the growth of central nervous system (CNS), kidney and breast cancer cell, with a GI50 value ranging from 0.6 to 12.8 μM .
    Anticancer agent 224
  • HY-N3193

    Others Neurological Disease
    Neritaloside could be isolated from nerium oleander. Neritaloside has central nervous system (CNS) depressant effect [2.
    Neritaloside
  • HY-B0740S

    MK130-d3 (hydrochloride)

    5-HT Receptor Neurological Disease
    Cyclobenzaprine-d3 (hydrochloride) is the deuterium labeled Cyclobenzaprine hydrochloride. Cyclobenzaprine hydrochloride (MK130 hydrochloride) is a skeletal muscle relaxant and a central nervous system (CNS) depressant.
    Cyclobenzaprine-d3 hydrochloride
  • HY-125692

    Cholecystokinin Receptor Metabolic Disease
    L-740093 is a potent cholecystokinin-B receptor antagonist. L-740093 has excellent central nervous system (CNS) penetration .
    L-740093
  • HY-14758

    NG2-73

    GABA Receptor Neurological Disease
    Adipiplon (NG2-73) is a selective GABAA receptor positive allosteric modulator. Adipiplon is particularly useful in the research of a variety of central nervous system (CNS) disorders.
    Adipiplon
  • HY-19154

    NS 3

    Thyroid Hormone Receptor Neurological Disease
    Montirelin (NS 3) is an analog of thyrotropin-releasing hormone (TRH), and exhibits high affinity to TRH receptors. Montirelin exhibits potent effects to central nervous system (CNS) .
    Montirelin
  • HY-P1253

    Opioid Receptor Neurological Disease
    α-Endorphin (human) is a neuropeptide, that acts on the central nervous system (CNS) and peripheral nervous system (PNS). α-Endorphin (human) binds μ-opioid receptor, and exhibits analgesic efficacy. α-Endorphin (human) regulates sexual behaviors and pleasure felling .
    α-Endorphin (human)
  • HY-153615

    mGluR Neurological Disease
    CVN636 is a potent, orally active and selective mGluR7 allosteric agonist with an EC50 value of 7 nM for hu mGluR7. CVN636 has central nervous system (CNS) permeability .
    CVN636
  • HY-N2072

    Transcrocetin; trans-Crocetin

    iGluR Endogenous Metabolite Cancer
    Crocetin (Transcrocetin), extracted from saffron (Crocus sativus L.), acts as an NMDA receptor antagonist with high affinity . Crocetin is capable of crossing the blood-brain barrier and reach the central nervous system (CNS) .
    Crocetin
  • HY-124382

    TRP Channel Neurological Disease
    AS1928370 is a novel and central nervous system (CNS) penetrant TRPV1 antagonist and can prevent ligand-induced activation in vivo. AS1928370 is a promising agent for neuropathic pain treatment research .
    AS1928370
  • HY-15722
    SB-222200
    3 Publications Verification

    Neurokinin Receptor Neurological Disease Endocrinology
    SB-222200 is a potent, selective, orally active and blood-brain barrier (BBB) penetrant NK-3 receptor antagonist. SB-222200 is developed for central nervous system (CNS) disorders .
    SB-222200
  • HY-119974

    NSC-253272

    DNA/RNA Synthesis Bacterial Infection Cancer
    Caracemide (NSC-253272) inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide is a novel anticancer agent derived from a hydroxamic acid and has demonstrated to produce severe central nervous system (CNS) toxicity .
    Caracemide
  • HY-107730

    Neuropeptide Y Receptor Neurological Disease
    NPY5RA-972 is an orally active, central nervous system (CNS) penetrating, potent and selective NPY Y5 receptor antagonist that prevents feeding driven by activation of this receptor .
    NPY5RA-972
  • HY-111263

    Amyloid-β Neurological Disease
    NIAD-4 is a fluorophore for optical imaging of amyloid-β () in the central nervous system (CNS) for Alzheimer’s disease (AD). NIAD-4 binds to the same Aβ site with the binding affinity (Ki) of 10 nM .
    NIAD-4
  • HY-107790

    DNA/RNA Synthesis Neurological Disease
    5-Methoxyflavone, belonged to Flavonoid family, is a DNA polymerase-beta inhibitor and neuroprotective agent against beta-amyloid toxicity. possess central nervous system (CNS) depressant effect mediated through the ionotropic GABAA receptors.
    5-Methoxyflavone
  • HY-116819

    GCGR Metabolic Disease
    VU0453379 is a highly selective and central nervous system (CNS) penetrant positive allosteric modulator (PAM) of glucagon-like peptide-1R (GLP-1R) with an EC50 of 1.3 μM .
    VU0453379
  • HY-116819A

    GCGR Metabolic Disease
    VU0453379 hydrochloride is a highly selective and central nervous system (CNS) penetrant positive allosteric modulator (PAM) of glucagon-like peptide-1R (GLP-1R) with an EC50 of 1.3 μM .
    VU0453379 hydrochloride
  • HY-162232

    mGluR Neurological Disease
    mGluR2 agonist 1 (Compound 5b) is a potent and selective metabotropic glutamate 2 receptor (mGluR) agonist with an EC50 of 82 nM. mGluR2 agonist 1 can be used for the research of central nervous system (CNS) diseases .
    mGluR2 agonist 1
  • HY-B0770

    β-Arteether; (+)-Arteether; Arteether

    CXCR Parasite Infection Cancer
    Artemotil (β-Arteether) has antimalarial activity for the treatment of chloroquine-resistant Plasmodium falciparum malaria with an IC50 of 1.61 nM. Artemotil also has central nervous system (CNS) neurotoxicity and anorectic toxicity in rats, dogs and monkeys .
    Artemotil
  • HY-164307

    BLU 451; LNG-451

    EGFR Cancer
    Pebezertinib (BLU 451) is an orally active inhibitor for EGFR. Pebezertinib exhibits the ability to penetrate the central nervous system (CNS). Pebezertinib can be used for research about non-small cell lung cancer carrying EGFR exon 20 insertion .
    Pebezertinib
  • HY-15344A

    Others Neurological Disease
    (S,S)-Ketone monoester is a (S,S)-enantiomer of Ketone monoester (HY-15344). Ketone monoester elevates the AcAc and acetone levels, thereby produces sustained ketosis and significantly delays central nervous system oxygen toxicity (CNS-OT) seizures .
    (S,S)-Ketone monoester
  • HY-145778

    Somatostatin Receptor Neurological Disease
    AGI-41998 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A). AGI-41998 is a brain-penetrant compound. AGI-41998 has the potential for exploring the effects of SAM modulation in the central nervous system (CNS) and research of cancer disease .
    AGI-41998
  • HY-145777

    Somatostatin Receptor Neurological Disease Cancer
    AGI-43192 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A). AGI-43192 is a potent, but limited brain-penetrant compound. AGI-43192 has the potential for exploring the effects of SAM modulation in the central nervous system (CNS) and research of cancer disease .
    AGI-43192
  • HY-147399

    5-HT Receptor Neurological Disease
    5-HT7 agonist 2 is a potent 5-HT7 receptor agonist with an IC50 value of 28.7 nM. 5-HT7 agonist 2 can be used for research of central nervous system (CNS) disorders .
    5-HT7 agonist 2
  • HY-W186242

    Phosphodiesterase (PDE) Neurological Disease Inflammation/Immunology
    PDE4-IN-16 (compound 27) is a PDE4 inhibitor with an IC50 value of 3.61 μM. PDE4-IN-16 can be used for the research of inflammatory diseases and central nervous system (CNS) disorders involving elevated levels of cytokines .
    PDE4-IN-16
  • HY-150640

    ROCK Neurological Disease
    Rho-Kinase-IN-2 (Compound 23) is an orally active, selective, and central nervous system (CNS)-penetrant Rho Kinase (ROCK) inhibitor (ROCK2 IC50=3 nM). Rho-Kinase-IN-2 can be used in Huntington’s research .
    Rho-Kinase-IN-2
  • HY-P3800

    Neurokinin Receptor Neurological Disease Endocrinology
    [Glp5] Substance P (5-11) is an octapeptide. [Glp5] Substance P (5-11) is one of the main substance P fragments in rat central nervous system (CNS). [Glp5] Substance P (5-11) locally modulates dopamine release in rat striatum .
    [Glp5] Substance P (5-11)
  • HY-N2072R

    iGluR Endogenous Metabolite Cancer
    Crocetin (Standard) is the analytical standard of Crocetin. This product is intended for research and analytical applications. Crocetin (Transcrocetin), extracted from saffron (Crocus sativus L.), acts as an NMDA receptor antagonist with high affinity . Crocetin is capable of crossing the blood-brain barrier and reach the central nervous system (CNS) .
    Crocetin (Standard)
  • HY-W105505

    Biochemical Assay Reagents Neurological Disease Inflammation/Immunology
    SAMe-1,4-Butanedisulfonate, a natural compound, is a methyl donor in the central nervous system. SAMe-1,4-Butanedisulfonate has antidepressant activity. SAMe-1,4-Butanedisulfonate can be used for research of CNS disorders .
    SAMe-1,4-Butanedisulfonate
  • HY-121313

    BAY 10-6734

    Angiotensin Receptor Neurological Disease Endocrinology
    Embusartan (BAY 10-6734) is a brain-penetrant and effective AT1 receptor blocker. Embusartan inhibits Ang II binding to brain AT1 receptors in the nuclei of central nervous system (CNS) inside due to high lipophilic character. Embusartan is promising for research of sympathetic hyperactivity and hypertension .
    Embusartan
  • HY-P3609

    JNJ 38488502; FE 200665

    Opioid Receptor Neurological Disease
    CR 665 (JNJ 38488502) is a peripherally selective κ-opioid agonist. CR 665 can activate the kappa opioid receptor with EC50 value of 10.9 nM. CR 665 can be used for the research of peripheral pain .
    CR 665
  • HY-B1330

    Cholecystokinin Receptor Neurological Disease Endocrinology Cancer
    Proglumide is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide selective blocks CCK’s effects in the central nervous system (CNS). Proglumide has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide also has antiepileptic and antioxidant activities .
    Proglumide
  • HY-103354

    Cholecystokinin Receptor Neurological Disease Endocrinology Cancer
    Proglumide sodium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide sodium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide sodium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide sodium also has antiepileptic and antioxidant activities .
    Proglumide sodium
  • HY-P1333

    Opioid Receptor Apoptosis Caspase Endogenous Metabolite Neurological Disease
    Dynorphin A is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A can induce neuronal death, and can be used in the research of neurological disease .
    Dynorphin A
  • HY-122647

    VU0652957; VU2957

    mGluR Neurological Disease
    Valiglurax (VU0652957) is a potent, orally active and selective mGlu4 positive allosteric modulator with EC50 values of 64.6 nM and 197 nM for hmGlu4/Gqi5 and rmGlu4 GIRK, respectively. Valiglurax is a central nervous system (CNS) penetrant. Valiglurax can be used in research of Parkinson's disease .
    Valiglurax
  • HY-14951
    Firategrast
    5+ Cited Publications

    SB 683699

    Integrin Neurological Disease
    Firategrast (SB 683699) is an orally active and specific α4β1/α4β7 integrin antagonist. Firategrast reduces trafficking of lymphocytes into the central nervous system (CNS) and decreases multiple sclerosis (MS) activity .
    Firategrast
  • HY-103354A

    Cholecystokinin Receptor Neurological Disease Endocrinology Cancer
    Proglumide hemicalcium is a nonpeptide and orally active cholecystokinin (CCK)-A/B receptors antagonist. Proglumide hemicalcium selective blocks CCK’s effects in the central nervous system (CNS). Proglumide hemicalcium has ability to inhibit gastric secretion and to protect the gastroduodenal mucosa. Proglumide hemicalcium also has antiepileptic and antioxidant activities .
    Proglumide hemicalcium
  • HY-P1333A

    Opioid Receptor Apoptosis Caspase Endogenous Metabolite Neurological Disease
    Dynorphin A TFA is an endogenous opioid peptide involved in inhibitory neurotransmission in the central nervous system (CNS). Dynorphin A TFA is a highy potent kappa opioid receptor (KOR) agonist, and is also an agonist for other opioid receptors, such as mu (MOR) and delta (DOR). Dynorphin A TFA can induce neuronal death, and can be used in the research of neurological disease .
    Dynorphin A TFA
  • HY-109189
    Rezivertinib
    1 Publications Verification

    BPI-7711

    EGFR Cancer
    Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib exhibits high potency against the common activation EGFR and the resistance T790M mutations. Rezivertinib has excellent central nervous system (CNS) penetration and has antitumor activity .
    Rezivertinib
  • HY-163806

    HDAC Neurological Disease Cancer
    NT376 is a high potency and selectivity inhibitor of class-IIa Histone deacetylases (HDAC) with an IC50 value of 32 nM, similar to NT160 (HY-149285) (IC50= 46 nM) in HT-29 cells. NT376 is proming for research of various cancers and in the diseases of the central nervous system (CNS) such as Alzheimer’s and Huntington’s diseases .
    NT376
  • HY-B0971

    Prophenpyridamine maleate; Tripoton maleate; Pheniramine maleate

    Histamine Receptor Apoptosis Inflammation/Immunology Endocrinology
    Pheniramine (Prophenpyridamine; Tripoton) maleate is a first-generation histamine H1 receptor antagonist, acts on the central nervous system (CNS) with sedative and hypnotic effect. Pheniramine maleate displays antitumor effect and induces leukemia cells apoptosis. Pheniramine maleate is also a safe and effective local agent that can suppress or relieve pain, with antipruritic effects .
    Pheniramine maleate
  • HY-B0971A

    Prophenpyridamine; Tripoton; Pheniramine solution

    Histamine Receptor Apoptosis Inflammation/Immunology Cancer
    Pheniramine (Prophenpyridamine;Tripoton) is a first-generation histamine H1 receptor antagonist, acts on the central nervous system (CNS) with sedative and hypnotic effect. Pheniramine displays antitumor effect and induces leukemia cells apoptosis. Pheniramine is also a safe and effective local agent that can suppress or relieve pain, with antipruritic effects .
    Pheniramine
  • HY-161846

    Tyrosinase Neurological Disease
    Tyrosinase-IN-31 (compound 2-06) is a central-targeting tyrosinase inhibitor (tyrosinase: monophenolase IC50=70.44 μM, diphenolase IC50=1.89 μM). Tyrosinase-IN-31 can inhibit the tyrosinase and melanogenesis. Tyrosinase-IN-31 can penetrate the BBB and enter the central nervous system (CNS). Tyrosinase-IN-31 shows neuroprotective effects and Parkinsonism behavior improving function .
    Tyrosinase-IN-31
  • HY-13011
    Alectinib
    Maximum Cited Publications
    32 Publications Verification

    CH5424802; RO5424802; RG7853

    Anaplastic lymphoma kinase (ALK) Cancer
    Alectinib (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively . Alectinib demonstrates effective central nervous system (CNS) penetration .
    Alectinib
  • HY-14905

    Tri-O-acetyl uridine

    Others Neurological Disease
    Uridine triacetate (Tri-O-acetyl uridine) is an orally active proagent of Uridine (HY-B1449). Uridine triacetate is quickly absorbed in the gut, and is rapidly deacetylated in the circulation to yield free uridine. Uridine triacetate is used for the research of 5-fluorouracil (5-FU) and capecitabine toxicity, or early-onset cardiac or central nervous system (CNS) .
    Uridine triacetate
  • HY-161331

    Cholinesterase (ChE) Neurological Disease
    S16–1029 is a selective and orally active butyrylcholinesterase (BChE) inhibitor with IC50s of 11.35 nM and 48.1 nM for eqBChE and hBChE, respectively. S16–1029 could cross the blood-brain barrier (BBB) and reach the central nervous system (CNS). S16–1029 can be used for Alzheimer's disease (AD) research .
    S16–1029

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: